T. Rowe Price reports 5.12M shares in Viridian Therapeutics (VRDN).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 5,123,592 shares, or 4.5%, of Viridian Therapeutics, Inc. (VRDN) common stock as of September 30, 2026. The filing indicates sole voting power over 5,123,546 shares and sole dispositive power over 5,123,592 shares, while explicitly denying that the filing constitutes an admission of beneficial ownership.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.